Document is current

Article History

Received: 29 April 2025

Accepted: 14 July 2025

First Online: 6 August 2025

Declarations

:

: Ethical committee approval and informed consent were waived because this was a retrospective service evaluation study registered with our institution’s Quality and Safety Information System (ID 2961 with registration number PRN8961), with board approval to publish obtained in January 2025. Research Ethics Committee of South Birmingham approval (IRAS ID 50895) and informed consent were obtained for the independent cohort of genetically confirmed BHDS patients recruited in the Molecular Pathology of Human Genetic Disease study.

: The clinical case included and discussed in this manuscript provided written consent for publication.

: G.D.S. declares financial relationships with the following companies: Evinova, British Journal of Urology International, NATCAN, National Institute for Health and Care Excellence, AstraZeneca, MSD. G.D.S. declares non-financial Interests with the following companies: Getting It Right First Time, British Association of Urological Surgeons, European Association of Urology. The remaining authors of this manuscript (A.S., T.S., J.B., A.Y.W., S.S., A.H.A., S.K., I.C., J.W., S.J.M., E.R.M., M.T.A.W.) declare no relationships with any companies, whose products or services may be related to the subject matter of the article.